Surgalign Holdings, Inc., a medical technology company, designs, develops, manufactures, and distributes biologic, metal, and synthetic implants worldwide. More Details
Slightly overvalued with worrying balance sheet.
Share Price & News
How has Surgalign Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SRGA's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: SRGA underperformed the US Medical Equipment industry which returned 15.8% over the past year.
Return vs Market: SRGA underperformed the US Market which returned 12% over the past year.
Price Volatility Vs. Market
How volatile is Surgalign Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall StHow RTI Surgical, Inc. (NASDAQ:RTIX) Can Impact Your Portfolio Volatility
1 year ago | Simply Wall StWhen Should You Buy RTI Surgical, Inc. (NASDAQ:RTIX)?
1 year ago | Simply Wall StDid RTI Surgical, Inc. (NASDAQ:RTIX) Insiders Buy Up More Shares?
Is Surgalign Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SRGA ($1.84) is trading below our estimate of fair value ($4.73)
Significantly Below Fair Value: SRGA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SRGA is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: SRGA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SRGA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SRGA has negative assets, so we can't compare its PB Ratio to the US Medical Equipment industry average.
How is Surgalign Holdings forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SRGA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SRGA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SRGA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SRGA's revenue is expected to decline over the next 3 years (-4.4% per year).
High Growth Revenue: SRGA's revenue is forecast to decline over the next 3 years (-4.4% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SRGA is forecast to be unprofitable in 3 years.
How has Surgalign Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SRGA is currently unprofitable.
Growing Profit Margin: SRGA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SRGA is unprofitable, and losses have increased over the past 5 years at a rate of 84.9% per year.
Accelerating Growth: Unable to compare SRGA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SRGA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).
Return on Equity
High ROE: SRGA has a negative Return on Equity (-555.38%), as it is currently unprofitable.
How is Surgalign Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: SRGA's short term assets ($181.2M) do not cover its short term liabilities ($282.9M).
Long Term Liabilities: SRGA's short term assets ($181.2M) exceed its long term liabilities ($2.3M).
Debt to Equity History and Analysis
Debt Level: SRGA's debt to equity ratio (405.7%) is considered high.
Reducing Debt: SRGA's debt to equity ratio has increased from 32% to 405.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SRGA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SRGA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 17.1% each year
What is Surgalign Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SRGA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SRGA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SRGA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SRGA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SRGA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Terry Rich (52 yo)
Mr. Terry M. Rich has been President, Chief Executive Officer and Director of Surgalign Holdings, Inc since July 2020. He was President of Global Spine at RTI Surgical Holdings, Inc., since December 3, 201 ...
|Chief Operating||3.08yrs||US$1.00m||0.70% |
|VP, General Counsel & Corporate Secretary||no data||US$820.50k||0.18% |
|Executive Vice President of Global Operations||no data||US$555.11k||0.096% |
|President of Global OEM||0.83yr||US$577.43k||0.17% |
|President||0.25yr||no data||0.36% |
|VP & Chief Accounting Officer||no data||no data||0.096% |
|Director of Corporate Communications||no data||no data||no data|
|Executive Vice President of Marketing||0.17yr||no data||no data|
|Executive Vice President of Human Resources||0.33yr||no data||no data|
|Executive Vice President of International||no data||no data||no data|
|Chief Commercial Officer||0.33yr||no data||0.16% |
|Executive Vice President of Research and Clinical Affairs||0.33yr||no data||no data|
Experienced Management: SRGA's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
|President||0.25yr||no data||0.36% |
|Independent Director||4.33yrs||US$162.90k||0.12% |
|Independent Director||1.58yrs||US$133.33k||no data|
|Lead Independent Director||0.25yr||US$165.00k||0.11% |
|Independent Director||4.33yrs||US$160.00k||0.14% |
|Independent Director||4.83yrs||US$167.50k||0.14% |
|Independent Director||6yrs||US$168.30k||0.15% |
|Independent Chairman||0.25yr||no data||0.35% |
Experienced Board: SRGA's board of directors are not considered experienced ( 3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.4%.
Surgalign Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Surgalign Holdings, Inc.
- Ticker: SRGA
- Exchange: NasdaqGS
- Founded: 1997
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$148.766m
- Shares outstanding: 80.85m
- Website: https://www.surgalign.com
Number of Employees
- Surgalign Holdings, Inc.
- 520 Lake Cook Road
- Suite 315
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SRGA||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Aug 2000|
|RT2||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Aug 2000|
Surgalign Holdings, Inc., a medical technology company, designs, develops, manufactures, and distributes biologic, metal, and synthetic implants worldwide. It offers coflex interlaminar stabilization devic ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/30 03:28|
|End of Day Share Price||2020/10/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.